Ipsen: Growth Platforms and Pipeline Candidates Should Help Offset Generic Erosion of Somatuline

Ipsen’s growth platforms of Dysport, Decapeptyl, Cabometyx, and Onivyde are continuing to drive sales for the company and offset the negative impact of generic erosion on Ipsen’s key oncology drug, Somatuline. We maintain our favorable view of Ipsen, and we like that its pipeline candidates are continuing to make progress. In February 2024, Ipsen received approval from the US Food and Drug Administration for Onivyde, a new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma. Additionally, in 2024 Ipsen is on track to launch elafibranor in second-line primary biliary cholangitis in the United States and in the European Union, as well as odevixibat in Alagille syndrome in the European Union.